Avalo Therapeutics announced progress on AVTX-010, a next-generation long-acting anti-IL-1β monoclonal antibody aimed at treating hidradenitis suppurativa and other inflammatory diseases. The company plans to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027, following positive Phase 2 results from their lead drug abdakibart. AVTX-010 is designed for less frequent dosing, potentially improving patient adherence and experience. Avalo is also advancing abdakibart into a pivotal Phase 3 trial, supported by recent financing and productive FDA engagement.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
